. 2019 Apr 1;36(2):124–135. doi: 10.12701/yujm.2019.00157

Table 2.

Univariate analysis of prognostic factors in entire group with residual rectal cancer patients after preoperative CRT

Clinicopathological characteristic	n (%)	Recurrence free survival			Cancer-specific survival
Clinicopathological characteristic	n (%)	p-value^a)	HR	95% CI	p-value^a)	HR	95% CI
Age (yr)
<60	70 (47.9)	0.676	0.897	0.538-1.495	0.426	0.779	0.420-1.443
≥60	76 (52.1)	0.676	0.897	0.538-1.495	0.426	0.779	0.420-1.443
Sex
Male	102 (69.9)	0.853	1.053	0.609-1.820	0.864	1.059	0.548-2.045
Female	44 (30.1)	0.853	1.053	0.609-1.820	0.864	1.059	0.548-2.045
Pretreatment CEA^b) (ng/mL)
<5	91 (66.9)	0.580	1.168	0.674-2.023	0.217	1.502	0.784-2.879
≥5	45 (33.1)	0.580	1.168	0.674-2.023	0.217	1.502	0.784-2.879
Tumor distance from anal verge (cm)
<5	112 (76.7)	0.609	1.170	0.642-2.132	0.384	1.358	0.680-2.711
≥5	34 (23.3)	0.609	1.170	0.642-2.132	0.384	1.358	0.680-2.711
Residual tumor size (cm)
<6.0	72 (49.3)	0.022	1.830	1.083-3.091	0.009	2.344	1.214-4.528
≥6.0	74 (50.7)	0.022	1.830	1.083-3.091	0.009	2.344	1.214-4.528
ypT category
T1	4 (2.7)
T2	33 (22.6)	<0.001	0.705	0.085-5.856	<0.001	0.357	0.037-3.431
T3	100 (68.5)		2.045	0.281-14.870		1.334	0.182-9.802
T4	9 (6.2)		14.972	1.843-121.603		10.437	1.272-85.655
ypN category
N0	99 (67.8)	<0.001			<0.001
N1	27 (18.5)		1.298	0.656-2.569		0.291	1.049-5.005
N2	20 (13.7)		3.543	1.918-6.546		6.262	3.076-12.746
Pathologic TNM stage
I	31 (21.2)	0.005			<0.001
II	68 (46.6)		2.327	0.959-5.644		1.577	0.514-4.841
III	47 (32.2)		3.833	1.575-9.326		5.04	1.747-14.541
Downstage
Yes	92 (63.0)	0.024	0.558	0.334-0.931	<0.001	0.331	0.178-0.616
No	54 (37.0)	0.024	0.558	0.334-0.931	<0.001	0.331	0.178-0.616
Tumor regression grade
0	4 (2.7)	0.014			0.001
1	21 (14.4)		0.308	0.084-1.124		0.304	0.082-1.130
2	55 (37.7)		0.232	0.069-0.774		0.179	0.052-0.619
3	66 (45.2)		0.173	0.052-0.582		0.122	0.035-0.434
Lymphatic invasion
No	112 (76.7)	0.004	2.161	1.259-3.710	<0.001	2.903	1.558-5.409
Yes	34 (23.3)	0.004	2.161	1.259-3.710	<0.001	2.903	1.558-5.409
Perineural invasion
No	112 (76.6)	<0.001	2.811	1.656-.4.770	<0.001	4.866	2.633-8.993
Yes	34 (23.3)	<0.001	2.811	1.656-.4.770	<0.001	4.866	2.633-8.993
Venous invasion
No	141 (96.6)	<0.001	40.488	11.990-136.718	<0.001	13.699	5.196-36.120
Yes	5 (3.4)	<0.001	40.488	11.990-136.718	<0.001	13.699	5.196-36.120
Circumferential resection margin (mm)
Positive (≤1)	30 (20.5)	<0.001	3.563	2.088-6.080	<0.001	3.803	2.034-7.110
Negative (>1)	116 (79.5)	<0.001	3.563	2.088-6.080	<0.001	3.803	2.034-7.110
KRAS mutation^b)
Negative	76 (72.4)	0.107	1.662	0.890-3.104	0.122	1.776	0.849-3.718
Positive	29 (27.6)	0.107	1.662	0.890-3.104	0.122	1.776	0.849-3.718
BRAF mutation^b)
Negative	101 (96.2)	0.435	1.747	0.422-7.223	0.186	2.543	0.605-10.684
Positive	4 (3.8)	0.435	1.747	0.422-7.223	0.186	2.543	0.605-10.684

CEA, carcinoembryonic antigen; CRT, chemoradiotherapy; HR, hazard ratio; CI, confidence interval; TNM, tumor, node, metastasis.

^a)

p-values were calculated using log-rank test.

^b)

Missing value is included.